Bascom Palmer annual angiogenesis meeting preview: Shedding light on neovascular and exudative ocular disease

Bascom Palmer Eye Institute will hold its 18th annual meeting, titled Angiogenesis, Exudation, and Degeneration 2021, a virtual event set for February 12-13.

Bascom Palmer Eye Institute’s 18th annual meeting, titled Angiogenesis, Exudation, and Degeneration 2021, is a virtual event slated for February 12-13.

The program promises to highlight the latest pharmacotherapies in the pipeline and those in clinical practice for managing neovascular age-related macular degeneration, macular edema, diabetic retinopathy, and retinopathy of prematurity, with a special focus on the current and future financial impact of these drugs on clinical practices and Medicare.

Retina specialists, general ophthalmologists, and researchers can benefit from the latest information on imaging, translational research, and clinical trials, with an emphasis on how these results will affect clinical ophthalmology. The presenters promise to focus on early phase clinical trials and recently completed studies on the treatment of a wide range of retinal diseases.

This year’s course codirectors are Philip J. Rosenfeld, MD, PhD; Harry W. Flynn Jr., MD; and Thomas A. Albini, MD, all from Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami.

The link for registration is https://umiamihealth.org/bascom-palmer-eye-institute/healthcare-professionals/continuing-medical-education/angiogenesis

Registration reservations must be received by noon EST Tuesday, February 9. Conference registration is $100 and the number of registrants is limited.

Conference program

The offerings on Friday, February 12, include 3 sessions. Following opening remarks by the codirectors, the presentation will commence at 8 AM.

Session I: Imaging Normal and Non-Exudative AMD Eyes includes the following:

Ultrahigh Resolution SD-OCT in Normal Aging and AMD, James G. Fujimoto, PhD

Quantitative Measurements of 3D Choroid and Choriocapillaris Using SS-OCT, Ruikang (Ricky) Wang, PhD

Changes in the Choriocapillaris and Choroid Associated with AMD Progression, Philip J. Rosenfeld, MD, PhD

Computational Modelling for Assessing OCT Biomarkers of Geographic Atrophy Growth, Eric M. Moult, BSc

The Status of the Choriocapillaris in Nascent GA, Robyn Guymer, MBBS, PhD, FRANZCO, FAHMS

Rate of Progression of iRORA to cRORA in AMD, David Sarraf, MD

Session II: Imaging Eyes With Exudative AMD will begin at 9:30 AM and feature:

OCTA Biomarkers for CNV Secondary to AMD, Seung-Young Yu, MD

Detection of Exudative AMD at Earliest Onset Yields New Information on Lesion Morphology, Usha Chakravarthy, MD

Multimodal Imaging Features and Clinical Relevance of Subretinal Lipid Globules, K. Bailey Freund, MD

Home OCT Based Management of Neovascular AMD, Anat Loewenstein, MD

Session III: Emerging Therapies for Non-Exudative AMD, beginning at 10:30 AM, is the final session of the day and will include:

Rationale, Modeling, and Pharmacokinetic Studies of Apolipoprotein A-I Mimetic L-4F for Dry AMD, Christine A. Curcio, PhD

Results of a Phase 1/2 Study on Gene Therapy for the Treatment of Geographic Atrophy, Nadia K. Waheed, MD, MPH

C5 Inhibition with Avacincaptad Pegol for the Treatment of Geographic Atrophy, Pravin U. Dugel, MD

Inhibition of Complement C3 in Geographic Atrophy with NGM621: Phase 1 Study Results, Charles C. Wykoff, MD, PhD

C3 Inhibition with Pegcetacoplan for the Treatment of GA in AMD, Cedric G. Francois, MD, PhD

Is it Valid to Use CAM OCT Criteria for Macular Atrophy in Interventional Non-Neovascular and Neovascular AMD Clinical Trials?, Glenn J. Jaffe, MD

Impact of Pegcetocoplan on Progression of Nascent Atrophy in AMD, SriniVas R. Sadda, MD

Update on Elamipretide for the Treatment of AMD , Jeffrey S. Heier, MD

On Saturday, February 13, attendees will reconvene at 8 AM.

Session IV: Emerging Therapies for Exudative AMD, will feature the following speakers:

The Efficacy and Safety of IBI 302, a Bispecific Antibody for the Treatment of Exudative AMD, Fenghua Wang, MD

Axitinib— A Novel TKI Delivered by Suprachoroidal Injection for AMD, David M. Brown, MD

KSI-301: Intravitreal Antibody Biopolymer Conjugate that Demonstrates Extended Durability in Wet AMD and Retinal Vascular Diseases, Diana V. Do, MD

Port Delivery System (PDS) for Exudative AMD: Archway Phase 3 Study Results, Carl D. Regillo, MD

Brolucizumab Inflammation Update, Thomas A. Albini, MD

Session V: Gene Therapy for Exudative AMD and Diabetic Retinopathy, begins at 9:15 AM and will include:

Subretinal Gene Therapy for Exudative AMD and Diabetic Retinopathy, Allen C. Ho, MD

Intravitreal Gene Therapy for Exudative AMD and Diabetic Retinopathy, Arshad Khanani, MD, MA

Suprachoroidal Gene Therapy for Exudative AMD and Diabetic Retinopathy, Peter A. Campochiaro, MD

Session VI: Dual Inhibition of Ang2 and VEGF for the Treatment of DME and Exudative AMD--An Update from the Faricimab Program is scheduled to begin at 10:00 AM. The following presentations are scheduled:

Rationale for Ang2 Inhibition in Exudative AMD and Diabetic Macular Edema, Karl G. Csaky, MD, PhD

Faricimab Update in Exudative AMD, Jeffrey S. Heier, MD

Faricimab Update in Diabetic Macular Edema, Charles C. Wykoff, MD, PhD

Session VII: Diabetes, Choroiditis, Retinitis Pigmentosa and Late Breaking Reports, the final one of the conference, begins at 11:00 AM and features:

AXT-107: Potential Role in Neovascular AMD, Diabetic Macular Edema, and Retinal Vein Occlusion, Quan Dong Nguyen, MD, MSc

Widefield SS-OCT Imaging of Diabetic Retinopathy, Harry W. Flynn Jr., MD

Anti-VEGF in the Treatment of Nonproliferative Diabetic Retinopathy, Jennifer K. Sun, MD

Correlation Between Baseline Retinal Non-Perfusion Area and Outcomes in the PANORAMA Study, Dilsher S. Dhoot, MD

Are There Two Forms of Multiple Evanescent White Dot Syndrome (MEWDS)?, Lawrence A. Yannuzzi, MD

Retinal Progenitor Cell Injections for Retinitis Pigmentosa, David S. Boyer, MD

Intravitreal Hydrogel-Based Axitinib Implant (OTX-TKI) for the Treatment of Neovascular AMD: Phase 1 Trial Update, Andrew A. Moshfeghi, MD, MBA